Reducing Size, Increasing Potential
What’s on the horizon for the field of nanomedicine?
Christian Jones | | Longer Read
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques. Read more about The Small Molecule Manufacturer here https://themedicinemaker.com/manufacture/small-but-never-forgotten
Let’s face the brutal truth; in many ways, the pharma industry can be inefficient – for example, spending an estimated $150 billion every year on R&D, but getting only around 50 to 60 products to market. The reality is that making medicines is a challenging business.
With all the “low fruit” seemingly plucked, molecules are also becoming more complex. Indeed, in today’s pharma pipeline, a large proportion of compounds in clinical development exhibit solubility and bioavailability issues – and there are chests of compounds whose development was terminated for the same reasons. Additionally, many people are looking at existing drugs and how they can be improved using the FDA’s 505(b)(2) regulatory pathway (which allows for approval based partly on data not developed by the drug sponsor) – for example, a high-dose product that is already approved can be made into a lower dose therapeutic by achieving better absorption in the body.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.